MOEA, TheratOcular Bioteck (TO) and ITRI together publicly announced the successful licensing and technology transfer of two new drug projects from ITRI to TO for ophthalmic unmet medical needs and future market entries. These collaborations signify a good beginning and great examples of government-industry partnership. The two projects are now both in clinical testing and are expected to acquire their first market approvals in 2025, according to Dr. Sean Chen, the President/CEO of TheratOcular Biotek.